Sodium adenosintriphosphate-Vial (Solution) Instructions for Use

Marketing Authorization Holder

Vial, LLC (Russia)

Manufactured By

NORTH CHINA PHARMACEUTICAL GROUP FORMULATION, Co., Ltd. (China)

ATC Code

C01EB10 (Adenosine)

Active Substance

Triphosadenine (DCF accepted for use in France)

Dosage Form

Sodium adenosintriphosphate-Vial

Solution for intravenous administration 10 mg/1 ml: amp. 5 pcs.

Dosage Form, Packaging, and Composition

1 ml – ampoules (10) – cardboard packs.

Clinical-Pharmacological Group

Drug improving metabolism of the myocardium, used for paroxysmal supraventricular tachyarrhythmias

Pharmacotherapeutic Group

Metabolic agent

Pharmacological Action

A means of improving metabolism and energy supply to tissues. ATP is a natural component of body tissues and is involved in many metabolic processes.

When ATP breaks down into ADP and inorganic phosphate, energy is released, which is necessary for muscle contraction and various biochemical processes.

ATP is involved in the transmission of excitation in adrenergic and cholinergic synapses and facilitates the transmission of excitation from the vagus nerve to the heart.

Apparently, ATP is one of the mediators that excite adenosine receptors. It enhances cerebral and coronary circulation and promotes an increase in peripheral circulation.

Triphosadenine is a derivative of adenosine.

Adenosine is an agonist of purinergic receptors, the activation of which leads to the inhibition of depolarization of the processes of conduction of electrical impulses in the sinus and AV nodes.

This effect underlies the antiarrhythmic action of triphosadenine in supraventricular tachycardias. It acts briefly for a few seconds.

Pharmacokinetics

After parenteral administration, it penetrates into the cells of organs, where it is broken down into adenosine and inorganic phosphate with the release of energy. Subsequently, the breakdown products are included in the resynthesis of ATP.

Indications

Relief of paroxysms of supraventricular tachycardia (excluding atrial fibrillation and/or flutter).

ICD codes

Dosage Regimen

Administer intravenously as a rapid bolus injection over 1-2 seconds.

For adult patients, use an initial dose of 10 mg (1 ml).

If the first dose is ineffective, administer a second dose of 20 mg (2 ml) after 1-2 minutes.

Do not exceed a single dose of 20 mg.

Inject directly into a large peripheral vein or a rapidly flowing intravenous infusion line.

Follow each injection with a rapid saline flush to ensure delivery to the systemic circulation.

Continuously monitor electrocardiogram (ECG) and blood pressure during and after administration.

Discontinue the drug immediately upon termination of the supraventricular tachycardia.

Use only in a setting with resuscitation equipment and personnel trained in its use.

This drug is not intended for pediatric use or for maintenance therapy.

Adverse Reactions

With intramuscular administration, headache, tachycardia, increased diuresis, hyperuricemia are possible.

With intravenous administration, nausea, facial skin hyperemia, headache, weakness are possible.

Allergic reactions rarely – itching, skin hyperemia.

Contraindications

Acute myocardial infarction, severe arterial hypotension, severe bradycardia, sick sinus syndrome, second- or third-degree AV block (except in patients with an artificial pacemaker), acute and chronic heart failure in the stage of decompensation, COPD, bronchial asthma, long QT syndrome, pregnancy, breastfeeding period, age under 18 years, hypersensitivity to triphosadenine.

With caution

Bradycardia, first-degree AV block, bundle branch block, atrial fibrillation and flutter, arterial hypotension, coronary artery disease, hypovolemia, pericarditis, heart valve stenosis, left-to-right arteriovenous shunt, cerebrovascular insufficiency, conditions after heart transplantation (less than 1 year).

Use in Pregnancy and Lactation

Contraindicated for use during pregnancy and breastfeeding.

Pediatric Use

Contraindicated for use in children and adolescents under 18 years of age.

Geriatric Use

Use with caution in elderly patients.

Special Precautions

Simultaneous use of triphosadenine and cardiac glycosides in high doses is not recommended.

Drug Interactions

With simultaneous use with cardiac glycosides, the risk of side effects (including arrhythmogenic action) increases.

Storage Conditions

Store at 2°C (36°F) to 8°C (46°F). Keep in original packaging, protected from light. Keep out of reach of children.

Dispensing Status

Rx Only

Important Safety Information

This information is for educational purposes only and does not replace professional medical advice. Always consult your doctor before use. Dosage and side effects may vary. Use only as prescribed.